

# **CRDMO Business Model: Accelerating Growth**

***2025 Interim Results***

**August 2025**







**Stock Code: 2269.HK**

This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our clients’ intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

## Use of Adjusted Financial Measures (Non-IFRS Measures)


We have provided adjusted net profit, adjusted net profit margin, adjusted gross profit, adjusted gross profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses, gains or losses from equity investments and foreign exchange gains or losses, and are not required by, or presented in accordance with, IFRS. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

# CONTENTS

-  **01** 2025 Interim Results
-  **03** Operation & Business Updates
-  **05** WBS & ESG as Key Components of Business Strategy
-  **02** 1H 2025 Financials Review
-  **04** Advanced Technology Platforms – Cornerstone of Future Success
-  **06** Summary & Outlook

**01**

## 2025 Interim Results



**742** <sup>16.4%</sup> → **864**  
Integrated Projects YoY

**86**  
New Projects Added

**16** <sup>50%</sup> → **24**  
Commercial Projects YoY

**18.5** → **20.3**  
Total Backlog (US\$ Bn) (Dec 24 → Jun 25)

**44 Regulatory Inspections**  
**with 100% Success**  
Number of Regulatory Inspections

**12,552/4,362** <sup>Key Talent</sup>  
<sup>Retention Rate</sup>  
<sup>98.8%</sup>  
Employees / Development Scientists



**8.6** <sup>16.1%</sup> → **10.0**  
Revenue (RMB Bn) YoY

**3.6** <sup>20.6%</sup> → **4.3**  
Adj EBITDA (RMB Bn) YoY


**2.5** <sup>11.6%</sup> → **2.8**  
Adj Net Profit (RMB Bn) YoY

**39.1%** <sup>360bps</sup> → **42.7%**  
Gross Profit Margin

**43.3% / 28.5%**  
Adj EBITDA Margin / Adj Net Profit Margin

**0.37** <sup>56.8%</sup> → **0.58**  
Basic EPS (RMB)






- Pre-IND revenue rose **35.2%** YoY in 1H 2025, driven by revenue conversion of wins across R services and pre-IND development.
- Early-phase revenue declined **29.7%** YoY in 1H 2025, primarily reflecting multiple large-scale projects progressing from early-phase to late development or CMO, and the impact of order timing.
- Late-stage + CMO revenue increased by **24.9%** YoY, reflects both evolution of projects from early-phases and the continued ramp-up of existing CMO programs.

# A 1H Record of 86 New Projects Added in 1H 2025, Highlight Continued Customer Demand & Execution Strength

- With leading technology, proven execution, and a growing global platform, the Company added **86** new integrated projects in 1H 2025 - reinforcing its role as a partner of choice for biopharma innovators globally
  - **Over half** of the **86** new projects from the **U.S.**
  - China also contributed to new project additions, as a stabilizing funding environment began to translate into increased customer activities
- Won **9** projects in 1H 2025, including **2** late-stage projects – the majority from U.S.-based clients
  - Most of these projects involve complex modalities, led by bi- & multi-specific antibodies and ADC
- **67** late-stage & **24 CMO** projects: forming a strong foundation for sustained future manufacturing revenue growth




**Notes:**

1. As of June 30, 2025

2. The commercial manufacturing projects refer to the projects approved by regulatory authorities and signed CMO contracts with the Group



# Backlog Remains at High Level to Support Future Growth





- As of Jun 30, 2025, total backlog reached **US\$20.3 bn**, of which **US\$11.4 bn** was service backlog.
  - Late-stage project advancement, commercial ramp-up and clinical progress of early-stage programs all contributed to the growth in service backlog.
- Upcoming potential milestone backlog reached **US\$9.0 bn**, reflecting accelerating R momentum.
- As of Jun 30, 2025, backlog within 3 years was **US\$4.2 bn**, enhancing near-term revenue visibility.
- Given the nature of our business, backlog does not fully reflect the cycle time of our businesses, hence R & D backlog is dwarfed by the long-duration CMO projects. We do not anticipate significant growth in backlog absent multi-year contract signing.

**Note:**  
1. Upcoming milestone revenue may take longer to receive at the various development stages as it depends on the success rate and progress of the projects  
2. Results may not foot due to rounding



# Rich Pipeline across All Biologics Modalities



■ 1H 2025 ■ 1H 2024



mAb



BsAb




Fusion Protein



ADC

- 338 First-in-class programs
- 168 bi- & multi-specifics covering different formats, several in phase III and commercial stage. Leveraging the Company's deep expertise and end-to-end capabilities, WuXi Biologics has captured expanding market opportunities in this sector
- 225 Antibody Drug Conjugates (ADC) projects with 34.7% YoY growth driven by sustained industry growth
- Ex-XDC, the remainder of WuXi Bio revenue grew by 9% YoY

1H 2025 New Project Split by Modality



- Recently bi- & multi-specifics, along with ADCs, have emerged as the industry's most critical segments. Our deep technical expertise in these complex modalities underpins our leading market position
- bi- & multi-specifics + ADCs > 70% of new signs


## Notes:

1. As of June 30, 2025, compared with projects number as of June 30, 2024


2. Bispecific Antibody (BsAb) Included both WuXiBody™ projects and non-WuXiBody™ projects




60.5% of Revenue



19.8% of Revenue



13.0% of Revenue



6.7% of Revenue

- **North America:** Revenue grew 20.1% YoY, driven by pre-IND momentum and expanded late-stage & CMO activities — highlighting sustained demand and project ramp-up despite evolving trade dynamics.
- **Europe:** Modest YoY growth of 5.7% driven by mix, with growth potential anticipated.
- **China:** Revenue declined 8.5% YoY, reflecting timing of customer orders, project progress and China license-out activities amid a gradually recovering market.
- **Rest of the World:** Revenue more than doubled YoY, reflecting the impact of strengthened BD efforts, with Japan and Korea sustaining strong growth momentum.

**Note:**

1. The ROW market primarily includes Singapore, Japan, South Korea, Australia and Brazil

The background features a light blue gradient with several protein ribbon structures. One structure is a light blue helix and sheet, another is a pink helix and sheet, and a third is a light blue helix. Overlaid on these are several curved lines in yellow, green, and blue. The text '1H 2025 Financials Review' is positioned in the upper right area, and the page number '02' is to its right.


## 1H 2025 Financials Review

**02**

# 1H 2025 Financial Performance


## Revenue

RMB mm




## IFRS Gross Profit

RMB mm




## Adjusted EBITDA <sup>(1)</sup>

RMB mm



## Adjusted Net Profit <sup>(2)</sup>

RMB mm



Unadjusted Margin %
  Adjusted Margin %
  Non-IFRS adjustments (SBC, Investment, FX and Divestiture Gain & Losses)


### Notes:

- Adjusted EBITDA represents net profit before (i) interest expenses, income tax expenses, listing expenses (ii) certain non-cash expenses, consisting of share-based compensation, amortization and depreciation and (iii) foreign exchange gains/losses and (iv) fair value gains/losses on investment portfolios and assets divestiture
- Adjusted net profit excludes the share-based compensation expenses, fair value gains/losses on investment portfolios, foreign exchange and asset divestiture gains/losses

# Key Profit Metrics


## IFRS Net Profit

RMB mm




## IFRS Net Profit Attributable to Owners of the Company

RMB mm




## Basic EPS <sup>(1)</sup>

RMB (Cents)



## Adjusted Basic EPS <sup>(1)</sup>

RMB (Cents)




### Note:

1. The authorized and issued shares of the Company were subdivided on the basis that every one (1) issued share is subdivided into three (3) subdivided shares (the "Share Subdivision"), which became effective on November 16, 2020. Basic and diluted earnings per share were stated after taking into account the effect of the Share Subdivision. Comparative figures have also been restated on the assumption that the Share Subdivision had been effective in the prior year.



# Gross Profit and Breakdown of Cost of Sales

## Cost of Services as % of Revenue



**Note:**  
1. Adjusted gross margin excludes the share-based compensation expenses

**AVAILABLE FUNDS**

- Available funds approx. **RMB12.5 bn** as of June 30, 2025
- Gearing Ratio **5.6%**, expect to have sufficient funds to sustain our growth

**CAPEX**

- 1H 2025 CAPEX approx. **RMB1.9 bn**, primarily allocated to the expansion of Biologics and XDC facilities in Singapore, Biologics facility in US, as well as XDC's expansion in China
- 2025 CAPEX Plan: approx. **RMB5.3 bn**

**LOAN**

- Approx. **RMB2.7 bn** borrowings as of June 30, 2025
- Available bank credit facilities of around **RMB6 bn**

**CASH FLOW**

- Free cash flow of RMB(0.09) bn in 1H 2025 due to timing
- Positive free cash flow to increase significantly in 2H 2025

## **03** Operation & Business Updates



# R-D-M Revenue Potential for Projects Embedded with WXB Proprietary Tech

	Most programs		CD3 TCEs programs	
	Revenue	GPM%	Revenue	GPM%
<b>R</b>		80%+		80%+
Upfront payment(1x)	up to \$30+m		up to \$40+m	
Milestone (cumulative)	up to \$200m+		up to \$200m+	
Sales royalties (recurring)	up to \$100m/yr for every \$1b sales		up to \$100m/yr for every \$1b sales	
<b>D</b>	fluctuates depending on clinical trial needs	50%+	fluctuates depending on clinical trial needs	50%+
Expect 600+ projects with cell line royalty <sup>1</sup> by YE2025				
<b>M – Manufacturing Services</b>	\$50m+/yr per \$1b sales	45%+	A few batches/yr for CD3 TCEs	45%+
<b>M – Cell line royalties<sup>1</sup></b>	typically 0.5% of net drug sales at 80%+ GPM%			


1. Cell line royalties are waived when sponsors manufacture 100% of commercial supply at WXB. Royalties apply to any portion of commercial production conducted outside WXB, providing a meaningful profit stream.

- **Upfront payment, milestone, sales and cell line royalties to become a significant portion of future revenue**
  - **Will drive Group margin expansion**



# Research Services Have Enabled 50+ Programs for Global Clients to Date

R Project Distribution by Phase



Previous analyses provide an industry benchmark of **10%** for the success rate in clinical development... Based on 18 leading pharmaceutical companies (2006-2022) and 274 new drug approvals, reveals an average likelihood of first approval rate of **14%**, broadly ranging from **8% to 23%**.


*Drug Discovery Today 2025*



## Biopharma Licensing:

### *Win-Win as New Asset Owners Expand Service Utilization & Award More Contracts*

The Contracts Signed Post Biopharma  
Licensing Collaboration<sup>1</sup>



- WuXi Bio held a leading position among bio-partnering programs utilizing CDMOs in 2024<sup>2</sup>
- Total contracts signed post-acquisition: US\$2,757m from 2018 to 1H 2025
- ~60% of contracts signed by MNCs
- WuXi Bio achieved ~90% project retention post biopharma licensing collaborations:
  - Revenue ↑↑↑ for acquired assets as new owners initiate larger and/or additional trials


**Note:**

1. During the period from 2018 to 1H 2025

2. Company's internal analysis



# Scheduled PPQs Underpin Future CMO Growth



- 25 PPQs scheduled for 2025E.
- PPQs scheduled for 2025E & 2026E are based on current contracts, providing visibility.
- 98%+ success rate for PPQ batches: among the industry's top performers, showcasing exceptional & reliable quality.

**Note:**  
1. PPQ = Process Performance Qualification, lead for commercial manufacturing



# Global End-to-End Capabilities to Deliver Integrated R, D & M Services

**3** RDM hubs  
EU/US, Singapore, and China

**150** INDs / Annual  
Project Capacity


**12** BLAs / Annual  
Project Capacity

**12,000+** Employees

**~500,000 L**  
Bioreactor Capacity

**16** DS  
Facilities

**9** DP  
Facilities



**5** Research Centers  
Shanghai WGQ, Shanghai FX, Chengdu in China, Boston in the U.S.; Singapore

**8** Development Centers  
Shanghai WGQ, Wuxi, Shanghai FX, Hangzhou, Suzhou, Chengdu in China; Cranbury NJ in the U.S.; Singapore

**8** Manufacturing Centers  
Wuxi, Shijiazhuang, Chengdu, Hangzhou in CHINA, Wuppertal in Germany; Dundalk in Ireland; Worcester MA in the U.S.; Singapore



- MFG6.2 successfully completed its first engineering and PPQ runs
- MFG7 completed its second 12,000L PPQ run
- Received its first EMA approval as a commercial manufacturing site for a global client's innovative biologic
- 100% success rate for PPQs
- During the Reporting Period, the Ireland site was honored with the prestigious 2025 Operational Excellence in Life Sciences Award at the Ireland Operational Excellence Awards

MFG6 & 7 in Dundalk, Ireland



## Massachusetts

- MFG11 likely the largest facility with single-use technology in the U.S.
  - Upstream 6 x 6K L bioreactors connected to 1 downstream line
  - High downstream throughput
  - Advanced automation
- When completed, WuXi Bio will provide end-to-end capabilities in the U.S.

## New Jersey

- MFG18 in Cranbury will undergo renovations to optimize capacities and improve efficiency
- DP12 in New Jersey GMP Readiness in Q2 2025

MFG11 & 18 in the U.S.



- The first commercial PPQ campaign was completed at the 15,000L line in MFG20 - Asia's first 5,000L drug substance scale-out line using single-use bioreactors
- This achievement highlights the Group's proven expertise in implementing single-use technologies for large-scale commercial manufacturing


MFG20 in Hangzhou, China





- Construction for a new modular Drug Product (DP) facility has begun. Design work is underway for a planned drug substance (DS) modular facility.
- Mechanical completion at the WuXi XDC manufacturing site was achieved in June 2025 - on schedule, under budget.
- Making solid strides according to the planned schedule to establish Singapore as another strategic hub for our global biologics Research, Development and Manufacturing.

## 15 months from piling start to WuXi XDC Mechanical Completion



Jan 2024



Mar 2024



Nov 2024



Aug 2024



Jan 2025




Jun 2025



# QUALITY is One of Our Key Competitive Advantages

Number of Regulatory Inspections Completed: 44

★ 100% successfully passed PLI



Number of License Approvals: 81 (115 by Facility)


Agency	Facility	MFG1	MFG2F	MFG2P	MFG4	MFG5	DP1	DP2	DP4	DP5	MFG3(CB)	MFG3	DP7
1	FDA (12)	WBPXXX WBPXXX WBPXXX WBPXXX	WBPXXX	WBPXXX		WBPXXX/ WBPXXX WBPXXX WBPXXX	WBPXXX WBPXXX WBPXXX	WBPXXX		WBPXXXX			WBPXXX
2	EMA (12)	WBPXXX WBPXXX WBPXXX	WBPXXX	WBPXXX	WBPXXX	WBPXXX/ WBPXXX	WBPXXX				WBPXXX		WBPXXX
3	NMPA (8)	WBPXXX WBPXXX		WBPXXX(2) WBPXXX		WBPXXXX WBPXXX WBPXXX	WBPXXX(2) WBPXXX WBPXXX	WBPXXXX	WBPXXX		WBPXXX	WBPXXX	
4	ANVISA (3)		WBPXXX WBPXXX		WBPXXX								
5	WHO (1)				WBPXXX								
6	TGA (2)		WBPXXX WBPXXX										
7	Hong Kong (1)		WBPXXX										
8	MHRA (5)	WBPXXX WBPXXX	WBPXXX	WBPXXX		WBPXXX/ WBPXXX WBPXXX/ WBPXXX	WBPXXX WBPXXX						
9	PMDA (4)	WBPXXX	WBPXXX	WBPXXX		WBPXXX WBPXXX	WBPXXX				WBPXXX		
10	Switzerland (3)	WBPXXX	WBPXXX	WBPXXX			WBPXXX						
11	United Arab Emirates (2)		WBPXXX										
12	Canada (3)		WBPXXX WBPXXX										
13	Saudi Arabia (1)					WBPXXX/ WBPXXX							
14	Costa Rica (1)												
15	Panama (1)												
16	Russian (1)												
17	New Zealand (2)		WBPXXX										
18	Thailand (1)												
19	Jordan (1)												
20	Malaysia (1)												
21	HSA (1)												
22	Sweden(1)												
23	Spain(1)												
24	Poland(1)												
25	Norway(1)												
26	Northern Ireland(1)												
27	Netherlands(1)												
28	Italy(1)		WBPXXX										
29	Greece(1)												
30	Germany(1)												
31	France(1)												
32	Finland(1)												
33	Denmark(1)												
34	Czechia(1)												
35	Austria(1)												
36	Australia(1) * New	WBPXXX		WBPXXX			WBPXXX						
# Approvals 115		17	30	12	3	22	17	3	2	1	4	2	2



Note:  
1. As of June 30<sup>th</sup>, 2025

# Key Quality and Regulatory Indicators: Consistently Achieving Favorable Results in Client Audits

## Major Findings per Audit



## Summary

**88** reports received as of 1H 2025 (total 139 client audits)

**0.67** (59/88) Major findings per Audit as of 1H 2025

1.45 (2019) → 0.84 (2020) → 0.65 (2021) → 0.33 (2022) → 0.55 (2023) → 0.49 (2024) → 0.67 (1H 2025)

**WuXi Biologics continues to safeguard our data integrity to maintain our strong track record with customers and regulators: no critical issues identified and zero data integrity findings.**

Note:

1. Figures excluded WuXi XDC



# Digital Solutions to Accelerate Science

## Win and Serve Our Clients



### DaVinci Client Portal

Best-in-class digital client experience with industry-leading, secure, cloud-based platform that enables clients to seamlessly generate proposals, access experimental data and reports, cost estimates, shipment tracking



## Lab Core Operating Systems and Analytics to Accelerate Discovery and Development



### BioFoundry

Digital twin representation of our physical lab processes, connected to lab devices and equipment with no-code configuration of workflows

400+ Workflows



### InSilico

In silico modeling and analytical methods used to minimize wet-lab experiments and improve processes

30+ Applications

## Manufacturing & Quality Control



### EBR

Electronic Batch Record (EBR) roll-out to improve quality, productivity, speed and flexibility

40% Productivity Increase




### Advanced Planning

Data and advanced analytics enabled planning and scheduling to effectively optimize labor, material, and equipment allocation to maximize utilization under complex scenarios

20% Efficiency Improvement



## Revenue per FTE on the Upward Trajectory



- Revenue per FTE set to grow sustainably, supported by efficiency gains from Digital and WBS, alongside higher-margin revenues from upfront payments, milestones, and royalties.

1. 2025 figure is based on mid-point of the 2025 revenue target



## **Advanced Technology Platforms – Cornerstone of Future Success**

**04**



# Ongoing Commitment to Cutting-Edge Technologies, Unlocking Vast Clinical Validation Opportunities

## Evolving WuXi XDC Proprietary Toolbox to Seize Industry Trend

### Conjugation Technologies...

**WuXiDAR<sup>X</sup> (1)**

- The upgraded version launched in 2024
- Clinical validated conjugation sites with DAR flexibility (1, 2, 4, 6) and great homogeneity
- An increasing number of customers are leveraging the platform to develop innovative modalities (i.e. AOC, APC and dual-payload ADC...)

**X-LinC**

- Launched in 2024
- Provide superior stability than Maleimide (the most popular connector currently in use) in *in vivo* and *in vitro* studies
- Significant potential for validation and adoption by clients seeking enhanced performance and stability

### Novel Payload-Linkers...

**WuXiTecan-1 and WuXiTecan-2**

- Newly launched in 1H 2025
- Showed great efficacy (CDX) and safety profile in mice and monkeys
- Customers are actively assessing the efficacy of WuXiTecan-1 and WuXiTecan-2, with potential collaboration under discussion

Abbreviations: AOC=Antibody Oligonucleotide Conjugate; APC=Antibody Peptide Conjugate; CDX = Cell line-derived xenograft model

Note:

1. Technology in collaboration with MCLICK-DAR1-A1/MCLICK-DAR2-A1/MCLICK-DAR6-A1 from Bio-reinnovation Tech. Ltd.



# Single-use Technology - The Growing Industry Norm Transforming Bioprocessing

## Cost - Efficiency


- Single-use tanks (SUTs) have a lower up-front capital investment, faster construction timelines & reduced indirect costs.
- Based on data from 300+ large-scale batches, WuXi Bio believes that current manufacturing costs using SUTs remain favorable, especially when savings realized combining SUTs with advanced bioprocessing technology platforms

## Manufacturing Efficiency & Flexibility

- WuXi Bio has implemented scale-out strategies, achieving large-scale production through parallel multiple SUB, with production scale up to 16,000L.
- This scale-out approach eliminates the complexity and risk of traditional non-linear scale-up, allowing capacity to flex quickly with changes in demand.
- Only 20% of commercial biologics require bioreactors > 10,000 L<sup>1</sup>.

## Sustainability

- Multiple studies have shown that SUT can significantly reduce the environmental footprint of biomanufacturing – using less energy, water and cleaning agents<sup>2</sup>
- For equivalent output, SUT can reduce water usage by up to 70%, lower electricity consumption by ~30%, and cut CO<sub>2</sub> emissions<sup>2</sup> by ~25%.
- These sustainability gains also help clients meet increasingly stringent ESG goals.




1. BPI Editors. Biomanufacturing supply and demand: industry trends and projected impacts. BioProcess Int, July 31, 2024.

2. Sinclair A et al. The environmental impact of disposable technologies. BioPharm Int 2008; 201-9.



# Single-Use Technology Scaled Out to Large Batch Sizes Comparable to Stainless Steel Tanks


Number of Successful Scale Out Batches (by year)




- 339 batches, 5 manufacturing facilities, 2 countries
- 97% successful rate overall, 98% since 2022

Disposable manufacturing proven to be cost-competitive, flexible & agile, effectively accommodating both small- and large-volume products

Number of Successful Scale Out Batches (by scale)



Successful Scale out info-by MFG#





# WuXiHigh™ 2.0 - Next-gen High-throughput DP Formulation Platform

**Concentration  
to 230mg/ml**

WuXiHigh™ 2.0 platform  
leverages proprietary  
excipient blends &  
formulation expertise to  
enable high-concentration  
DPs- up to 230mg/mL

**Viscosity -90%**


Reduces viscosity by up to  
90% without compromising  
formulation stability or  
injectability

**WuXiHigh™**

- WuXiHigh™ 2.0 enables formulation concentrations beyond the current FDA-approved high of 200mg/mL- delivering greater flexibility in injection volume, reduced dosing frequency, and simplified cold-chain logistics.
  - Also enhances manufacturing efficiency across both drug substance and drug product.
- This innovation reinforces our leadership in technology, speeds client programs and improves patient delivery.

**05**

## **WBS and ESG as Key Components of Business Strategy**





# WBS 1H 2025 Highlights

1 point

Improvement in  
gross margin

128+

Kaizen Projects



## Premier Quality

Enhance reporting standards  
Mitigate quality risk



## Revenue

Enhance customer retention  
Expand into new business



## Labor Efficiency

Deploy digital initiatives  
Implement standard work



## Material Cost Saving

Optimize material usage  
Improve inventory management



## Expense Saving

Optimize idle facilities  
Improve budget management



## ESG Optimization

Reduce energy, water,  
waste and CO<sub>2</sub> emissions



# Trustworthy Partner with a Strong Sustainability Commitment



Corporate Sustainability  
Assessment (CSA) 2024 Score

Member of  
**Dow Jones  
Sustainability Indices**  
Powered by the S&P Global CSA


**DJSI World Indices  
S&P Global ESG Indices**  
(2023-2025)




**MSCI ESG Ratings AAA  
MSCI Selection Indexes**  
(2023-2025)



**EcoVadis Platinum Medal  
Global 1%**  
(2023-2025)



**Sustainalytics Negligible-Risk  
Industry & Regional Top Rated**  
(2021-2025)



**A List – Water Security  
A List - Supplier Engagement  
Leadership - Climate Change**  
(2023-2025)



**FTSE4Good Emerging Index  
Industry Top 7%**  
(2021-2025)



**Prime Award  
ISS ESG Corporate Rating**  
(2023-2025)

\* Data As of July 31, 2025



The background features a light blue gradient with several protein ribbon structures. One structure is a light blue helix and sheet, another is a pink helix and sheet, and a third is a light blue helix and sheet. There are also several curved lines in yellow, green, and blue that sweep across the page.

## Summary & Outlook

**06**



# We Firmly Believe that the CRDMO Business Model is the Most Efficient in Our Industry



R

transforms innovative biotech concepts from across the globe into reality


D

accelerates project progress through our execution excellence & swift delivery

M

provides cost-competitive therapies to patients worldwide

Our Three Long-Term Growth Curves



- Over the last decade, WuXi Bio has achieved substantial growth by implementing our “Follow the Molecule” strategy, which led to significant revenue growth in Development (D).
- Having established key technology platforms, we believe that Research Services (R) will be another significant growth driver in the future.
- As a technology leader in modern biomanufacturing with a proven track record of delivering large commercial projects, we view Manufacturing (M) as another key pillar for future growth.

# Strong 1H25 Results Reinforce Confidence; Revenue Growth Target Raised to 14% - 16%

## 1H 2025: Strong Results Underscore Growth Trajectory

- Group revenue grew 16.1% YoY (continuing ops +20.2% YoY) and GPM expanded 360bps YoY
  - Pre-IND grew 35.2% YoY; recognized expertise in complex modalities
  - M rose 24.9% YoY
- D: record 1H with 86 new integrated projects signed
- M: 25 scheduled PPQs in FY25E (+56% YoY); multiple large-scale programs recently launched and/or expected to launch
- New order strength across late-stage advancement, commercial ramp, and early-stage clinical progress
- Asset optimization for greater operational agility, improved asset efficiency

- Accelerated growth ahead
  - R-D-M all engines on fire;
  - M momentum sustains, 27 PPQs scheduled for 2026 as of 1H25
- Margin expansion
  - Mix lift from R, WBS efficiency, higher utilization rates (multiple large-scale CMO projects)
- Strong FCF conversion underscoring high earnings quality
- Global expansion on track
- Technology innovation
  - Highly automated DS manufacturing
  - WuXiHigh™ (DP)
  - Effix™ Microbial



- ◆ FY25 revenue growth target raised to 14% – 16% from 12% – 15%
- ◆ Improved profitability and significant free cash flow in FY25

## **WuXi Biologics Vision**

**Every biologic can be made**

## **WuXi Biologics Mission**

**Accelerate and transform the discovery, development and manufacturing of biologics to enable our global partners and benefit patients worldwide**